HK1207587A1 - A dual met - vegf modulator for treating osteolytic bone metastases met-vegf - Google Patents
A dual met - vegf modulator for treating osteolytic bone metastases met-vegfInfo
- Publication number
- HK1207587A1 HK1207587A1 HK15108354.6A HK15108354A HK1207587A1 HK 1207587 A1 HK1207587 A1 HK 1207587A1 HK 15108354 A HK15108354 A HK 15108354A HK 1207587 A1 HK1207587 A1 HK 1207587A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- met
- vegf
- bone metastases
- dual
- modulator
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261641837P | 2012-05-02 | 2012-05-02 | |
PCT/US2013/039284 WO2013166296A1 (en) | 2012-05-02 | 2013-05-02 | A dual met - vegf modulator for treating osteolytic bone metastases |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1207587A1 true HK1207587A1 (en) | 2016-02-05 |
Family
ID=48428691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15108354.6A HK1207587A1 (en) | 2012-05-02 | 2015-08-27 | A dual met - vegf modulator for treating osteolytic bone metastases met-vegf |
Country Status (5)
Country | Link |
---|---|
US (1) | US9861624B2 (xx) |
EP (1) | EP2844254A1 (xx) |
JP (2) | JP2015515988A (xx) |
HK (1) | HK1207587A1 (xx) |
WO (1) | WO2013166296A1 (xx) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI577664B (zh) | 2009-01-16 | 2017-04-11 | 艾克塞里克斯公司 | N-(4-{〔6,7-雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺蘋果酸鹽、包含其之醫藥組合物及其用途 |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
KR101882328B1 (ko) | 2010-09-27 | 2018-07-27 | 엑셀리시스, 인코포레이티드 | 거세-저항성 전립선 암 및 골형성성 뼈전이의 치료용 met 및 vegf 이중 억제제들 |
US9717720B2 (en) | 2011-02-10 | 2017-08-01 | Exelixis, Inc. | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
BR212013028314U2 (pt) | 2011-05-02 | 2015-11-03 | Exelixis Inc | método para tratar câncer e dor de câncer de osso |
CA2848512A1 (en) | 2011-09-22 | 2013-03-28 | Exelixis, Inc. | Method for treating osteoporosis |
WO2013059788A1 (en) | 2011-10-20 | 2013-04-25 | Exelixis, Inc. | Process for preparing quinoline derivatives |
GEP20196995B (en) | 2013-03-15 | 2019-07-25 | Inc Exelixis | Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
EP2981263B1 (en) | 2013-04-04 | 2022-06-29 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
EP3738952A1 (en) | 2014-02-14 | 2020-11-18 | Exelixis, Inc. | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
US10159666B2 (en) | 2014-03-17 | 2018-12-25 | Exelixis, Inc. | Dosing of cabozantinib formulations |
CN104788372B (zh) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体 |
EP3174854B1 (en) | 2014-07-31 | 2022-08-24 | Exelixis, Inc. | Method of preparing fluorine-18 labeled cabozantinib and its analogs |
MX2017001490A (es) | 2014-08-05 | 2017-05-11 | Exelixis Inc | Combinaciones de farmacos para tratar mieloma multiple. |
US11141413B2 (en) | 2016-04-15 | 2021-10-12 | Exelixis, Inc. | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
CR20200358A (es) | 2018-01-26 | 2021-02-22 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
WO2024110606A1 (en) * | 2022-11-25 | 2024-05-30 | Synthon B.V. | A process for preparation of cabozantinib or tivozanib |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
JP4638436B2 (ja) | 2003-09-26 | 2011-02-23 | エグゼリクシス, インコーポレイテッド | c−Metモジュレーターおよびその使用 |
CA2572331A1 (en) | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
JP2008537748A (ja) | 2005-04-06 | 2008-09-25 | エクセリクシス、インコーポレイテッド | c−Metモジュレーター及び使用方法 |
CN101605540A (zh) | 2006-12-14 | 2009-12-16 | 埃克塞利希斯股份有限公司 | 使用mek抑制剂的方法 |
WO2008083319A1 (en) | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of enantiopure ilaprazole |
PL2183254T3 (pl) | 2007-08-29 | 2017-10-31 | Methylgene Inc | Inhibitory aktywności białkowej kinazy tyrozynowej |
TW200922590A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | VEGFR inhibitors containing a zinc binding moiety |
UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
CA2723617A1 (en) | 2008-05-14 | 2009-11-19 | Amgen Inc. | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
AR075084A1 (es) | 2008-09-26 | 2011-03-09 | Smithkline Beecham Corp | Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes |
EP2349328A1 (en) | 2008-10-01 | 2011-08-03 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
AU2009313970A1 (en) | 2008-11-13 | 2010-05-20 | Exelixis Inc. | Methods of preparing quinoline derivatives |
TW201028383A (en) | 2008-12-04 | 2010-08-01 | Exelixis Inc | Methods of preparing quinoline derivatives |
TWI577664B (zh) | 2009-01-16 | 2017-04-11 | 艾克塞里克斯公司 | N-(4-{〔6,7-雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺蘋果酸鹽、包含其之醫藥組合物及其用途 |
MX2012000809A (es) | 2009-07-17 | 2012-03-14 | Exelixis Inc | Formas cristalinas de n-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin- 4-ilpropil)oxi]-quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclop ropan-1,1-dicarboxamida. |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
CN102933551A (zh) | 2010-03-12 | 2013-02-13 | 埃克塞里艾克西斯公司 | N-[3-氟-4-({6-(甲氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺的水合结晶形式 |
US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
US20140186407A9 (en) | 2010-07-16 | 2014-07-03 | Exelixis Inc. | C-Met Modulator Pharmaceutical Compositions |
US9724342B2 (en) | 2010-07-16 | 2017-08-08 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
US20120089541A1 (en) | 2010-08-31 | 2012-04-12 | Genentech, Inc. | Biomarkers and methods of treatment |
WO2012044574A1 (en) | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
KR101882328B1 (ko) | 2010-09-27 | 2018-07-27 | 엑셀리시스, 인코포레이티드 | 거세-저항성 전립선 암 및 골형성성 뼈전이의 치료용 met 및 vegf 이중 억제제들 |
CN103391773A (zh) * | 2010-09-27 | 2013-11-13 | 埃克塞里艾克西斯公司 | 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂 |
WO2012064967A2 (en) | 2010-11-10 | 2012-05-18 | Cedars-Sinai Medical Center | Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases |
US20130252956A1 (en) | 2010-11-22 | 2013-09-26 | Howard Kallender | Methods of treating cancer |
US9717720B2 (en) | 2011-02-10 | 2017-08-01 | Exelixis, Inc. | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
BR212013028314U2 (pt) | 2011-05-02 | 2015-11-03 | Exelixis Inc | método para tratar câncer e dor de câncer de osso |
TW201306842A (zh) | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法 |
CA2848512A1 (en) | 2011-09-22 | 2013-03-28 | Exelixis, Inc. | Method for treating osteoporosis |
WO2013059788A1 (en) | 2011-10-20 | 2013-04-25 | Exelixis, Inc. | Process for preparing quinoline derivatives |
BR112014011009A2 (pt) * | 2011-11-08 | 2017-06-06 | Exelixis Inc | inibidor duplo de met e vegf para tratar câncer |
KR20140094597A (ko) * | 2011-11-08 | 2014-07-30 | 엑셀리시스, 인코포레이티드 | 암 치료를 정량하는 방법 |
EP2892532B1 (en) | 2012-09-07 | 2019-02-13 | Exelixis, Inc. | Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma |
US20140221372A1 (en) | 2013-02-06 | 2014-08-07 | GlaxoSmithKline Intellectual Property (NO 2.) Limited | Method of administration and treatment |
GEP20196995B (en) | 2013-03-15 | 2019-07-25 | Inc Exelixis | Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
CA2908815A1 (en) | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Drug combinations to treat cancer |
EP2981263B1 (en) | 2013-04-04 | 2022-06-29 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
-
2013
- 2013-05-02 WO PCT/US2013/039284 patent/WO2013166296A1/en active Application Filing
- 2013-05-02 JP JP2015510456A patent/JP2015515988A/ja active Pending
- 2013-05-02 US US14/398,188 patent/US9861624B2/en active Active
- 2013-05-02 EP EP13722238.6A patent/EP2844254A1/en not_active Withdrawn
-
2015
- 2015-08-27 HK HK15108354.6A patent/HK1207587A1/xx unknown
-
2018
- 2018-03-07 JP JP2018040526A patent/JP2018115174A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20150133494A1 (en) | 2015-05-14 |
JP2015515988A (ja) | 2015-06-04 |
WO2013166296A1 (en) | 2013-11-07 |
US9861624B2 (en) | 2018-01-09 |
EP2844254A1 (en) | 2015-03-11 |
JP2018115174A (ja) | 2018-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1207587A1 (en) | A dual met - vegf modulator for treating osteolytic bone metastases met-vegf | |
HK1216139A1 (zh) | 骨移植物分配系統 | |
GB2515712B (en) | System for binding bone | |
IL231741B (en) | A modulator device with a configuration for implantation | |
PL2925178T3 (pl) | Zamknięcie obrotowe do buta | |
PT2906696T (pt) | Métodos para modular a expressão de c9orf72 | |
ZA201500401B (en) | Methods ok making flexible containers | |
AU350840S (en) | Stopper for a carafe | |
EP2935704A4 (en) | COUPLER | |
GB2513497B (en) | Apparatus for inventory control | |
ZA201402370B (en) | A tibial component | |
HK1244296B (zh) | 改性膠原 | |
PL2879622T3 (pl) | Sterowanie ortez | |
EP2893650A4 (en) | METHOD AND DEVICE FOR PROVIDING CHANNEL HEALTH FOR WDM SYSTEM | |
EP2802284A4 (en) | DENTAL WEDGE | |
GB2506673B (en) | A method for inferring clutch engagement state | |
GB2492898B (en) | Attachment for a shoe | |
EP2908858A4 (en) | METHODS OF INHIBITING OSTEOLYSIS | |
PL2617277T3 (pl) | Pług obracalny | |
GB201203399D0 (en) | A plaster scraper | |
GB2509385C (en) | System for a snowboarder | |
GB2500675B (en) | A first aid footwear package | |
ZA201307407B (en) | A prosthesis | |
PL2892313T3 (pl) | Pług obrotowy | |
ZA201305468B (en) | Connecting mechanisms for a guy-wire |